Verona Pharma released additional results of a Phase 2 trial demonstrating that maintenance treatment with its dry powder inhaler…
Ana Pena, PhD
Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Ana Pena, PhD
A finger-prick blood test could help guide antibiotic prescriptions for people with chronic obstructive pulmonary disease (COPD) during a …
Scientists have found data to support an optimal threshold for lung function that can accurately diagnose clinically significant airflow obstruction…
Theravance Biopharma and Mylan have agreed to extend the development and commercialization of Yupelri (inhalation solution of…
A post-hoc analysis showed that nebulized ensifentrine (RPL544) is highly effective for relieving respiratory symptoms in chronic obstructive pulmonary…
The triple therapy inhaler Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol) has received a positive…
Consistent support from healthcare professionals, interaction with peers, and regular exercise can help people with chronic…
Nearly 100 million Chinese adults have COPD, but most don’t know they do, a study reported. Heavy air…
Grifols, a global healthcare company, has launched the “Look into Genetic COPD…
The U.S. Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) submitted by Theravance Biopharma and…